Clinical Trial Update: To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial assessing olaparib maintenance monotherapy in BRCA or HRR+ mutated ovarian cancer; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: BRCA or HRR+ Mutated Ovarian Cancer Patients | Phase 4 | Status: COMPLETED | Results posted: 2021-06-18